AusVir Therapeutics

AusVir Therapeutics is an Australian biotechnology company focused on developing first-in-class antiviral therapies for respiratory viruses, specifically Human Parainfluenza Virus (hPIV). The company's lead program is based on research from Griffith University's Institute for Glycomics, targeting the viral sialidase to prevent infection and spread. Currently, there are no approved vaccines or antiviral drugs for hPIV, positioning AusVir to address a significant unmet medical need in pediatric and immunocompromised populations. Its lead candidate, AV-001, is a small molecule inhibitor designed to block the activity of the hPIV neuraminidase/sialidase protein. AusVir aims to advance this candidate through clinical development to provide the first specific treatment for hPIV-related respiratory disease.